Fidelity SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

IntelGenx Technologies Corp. (IGXT)

Add IGXT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator GaryJPalys, kyouter
Search This Board:
Last Post: 9/19/2014 8:08:03 AM - Followers: 185 - Board type: Free - Posts Today: 0

IntelGenx Technologies Corp

Listing Exchanges: OTCQX as IGXT and Toronto Venture Exchange: IGX.V

Current partners include, Edgemont Pharma, Pacific Therapeutics, Dava Pharmaceuticals, RedHill Biopharma, and PAR Pharmaceuticals. We are in discussions with other potential partners for some of our other products.

Our unique proprietary platform delivery technologies offer many benefits to our partners including:
Broad range of delivery profiles
Convenient and versatile products
High quality products

Business Strategy
Our business strategy is to apply our drug delivery technologies to improve existing drug compounds with proven efficacy and safety and, in conjunction with
strategic development and distribution partners, reintroduce these drug compounds to the market as branded products with improved deliverability and efficacy. 

Because we are developing improved formulations of currently marketed therapeutics, our products typically require fewer clinical trials to generate the safety and
efficacy data needed to achieve regulatory approval than drug formulations that have not been previously marketed. As a result, we believe we can accelerate
development and reduce risk compared to traditional pharmaceutical and biotechnology companies. 

Using the 505(b)(2) approach to obtain FDA approval, our products have the possibility of obtaining  three years of market exclusivity.


IntelGenx (IGX / IGXT) Announces Commercial Launch of Forfivo XL(TM) in USA - Viral News

(Click the link below to watch video)

    Forfivotm XL Launch Video


(Click on picture below to go to website)


Friday, October 5, 2012

Withdrawal of Teva's Budeprion XL 300 from the US market should benefit IntelGenx Technologies

USFDA has asked Teva to wihdraw - Budeprion XL 300 from the US.
  According to USFDA, Budeprion XL 300 is no bioequivalent to Welbutrin XL 300.
  It has been found that Budeprion XL 300 releases the active ingredient faster than the original drug Welbutrin XL 300.
The USFDA reviewed the Budeprion XL, after several patients complained 
about head aches, anxiety and insomnia.

We think the withdrawal can be positive for IntelGenx
which is preparing to launchForfivo ( bupropion extended release 450mg)
and should help the launch trajectory for Forfivo. 
Forfivo will be marketed by Edgemont pharmaceuticals in the US.
Edgemont focuses exclusively on launching specialty drugs aimed at the neuropsychiatry sector,
and has one drug on the market - high-dose fluoxetine (Prozac).

Forfivo is the only single tablet that is formulated to deliver a dose of 450mg.
Until now, those patients who need to take the highest dose (450mg)
of bupropion XL need to take multiple tablets of lower-strength doses as there.

Market Opportunity

In 2011, total branded and generic sales of extended-release bupropion
totaled $745 million, of which 
roughly 20% was for the highest dose (450mg).


IntelGenX Corporate Presentation June 2014

Click on the image below
June, 2014



                                     The archive for all Intelgenx Presentations from 2007 to 2014 can be found here:


March 12th, 2012 -   Cleland Fund comments regarding their investment insight for IGXT: 

March 12, 2012 -   BluMont Capital Corporation - Northern Rivers Funds - 70 University Avenue - Suite 1200, PO Box 16 - Toronto, ON M5J 2M4 - Canada - Tel: 416.597.1226 - Fax: 416.597.8926

The Northern Rivers Innovation RSP Fund ("the Innovation Fund" or "the Fund") Dear Partners and Friends: Let's go through the major holdings…(Below is just the IGXT portion)

INTELGENX: FDA approval for their 1st drug in November + a commercialization partner for that drug + a deal with Par Pharmaceuticals = lower share price??? This is a completely irrational situation, making IntelGenx a table pounder. As of the close on March 7, the stock is LOWER than it was before CPI-300 (IntelGenx' antidepressant) received FDA approval; LOWER than it was before the deal with Par Pharmaceutical; and LOWER than it was before the announcement of its commercialization partner for CPI-300. I would argue that at $0.55 or lower, the only thing an investor is paying for is CPI-300, meaning that you are getting the entire thin-film delivery platform and 9 drug pipelines for FREE. Notably, there are only a handful of thin-film companies out there, and IntelGenx is one of only two that are publicly traded (that I am aware of). As thin-films become more recognized for their value to big pharma over the coming years, the scarcity value of thin-film platforms will ultimately result in IntelGenx' thin-film platform and pipeline receiving a premium valuation; right now, there is NO value. Ridiculous. I have put my money where my mouth is recently, and bought shares in the open market for the second of the two funds I run. To a certain degree, however, I understand what has happened: there was (unbeknownst to me or management) a scummy promote on IntelGenx last summer, in which CPI-300 was hyped as a billion dollar drug. Anyone who knows anything about CPI-300 and its market knows that that is complete crap. In fact, CPI-300 is the smallest revenue potential drug within IntelGenx' pipeline, with peak revenue to Intelgenx' commercialization partner maybe in the $60-$100million range. This means that reality has been a big let-down to those who bought into the billion dollar dream. But the fact is that the commercialization deal and FDA approval for CPI-300 do two very important things for IntelGenx: 1) Getting CPI-300 approved by the FDA provided concrete illustration that IntelGenx has the skill set to negotiate the 505b2 pathway to drug approval, which involves both dealing with the FDA and dealing with the court system. For me, that validation will ultimately lower the discount rate that is applied to the rest of IntelGenx' pipeline. 2) The upfront, milestone and royalty payments from the commercialization deal for CPI-300 arguably cover all of IntelGenx' development costs for its pipeline of thin-film 505b2 drugs. If this sounds far-fetched, recall that the 505b2 pathway to drug approval is dramatically different than the conventional PhaseI-II-III pathway, because IntelGenx is simply moving existing, already-FDA-approved drugs onto a different delivery platform. i.e., IntelGenx is working on projects such as moving Cialis and a migraine drug onto a thin-film platform. It is a cheap, and extremely low-risk pathway to getting a drug to market. The CPI-300 deal with Edgemont Pharmaceuticals: a source of disappointment for the market; a source of confidence for me On February 14, IntelGenx announced a commercial license agreement for CPI-300 with Edgemont Pharmaceuticals. The deal provided for $1M upfront for IntelGenx and a series of milestones that could reach $28.5M over the life of the agreement. According to the company up to $4M of these milestones are achievable at the product launch or shortly thereafter. IntelGenx is also entitled to a double digit royalty on net product sales. The market reaction thus far to the deal has been negative. It seems many people were perhaps speculating on a more prominent partner and/or better economics in the deal. However, I think the markets have misinterpreted the quality of the deal, I think in part due to misjudging Edgemont but also misunderstanding what CPI-300 means to IntelGenx. On the former, Edgemont is a smaller private company that has very little visibility to people outside the industry. But a closer inspection reveals a company with a sales and marketing focus on neurology, a CEO who formerly ran Novartis' CNS business in the US, and a Board populated with people from some of the most successful U.S. specialty pharma companies of the past 15 years. This last point is one of the nuances that the markets really seem to have missed. Two of the Edgemont Board members are former Kos Pharmaceuticals (formerly Nasdaq: KOSP) executives who now work for a private equity firm called Vatera Capital. For anyone who hasn't heard of Kos, they were arguably the most successful specialty pharma company in the U.S. in the past 15 years. They created a market for a prescription vitamin called Niaspan, which paved the way for future prescription vitamin and omega-3 companies like Reliant, Amarin and Neptune/Acasti. Kos was eventually bought by Abbott for $3.7B, and one of the founders Michael Jaharis took his money (he is estimated now to be worth $1.9B) and formed Vatera Capital to invest in businesses like Edgemont. So Vatera's investment in Edgemont gives me tremendous confidence that IntelGenx has landed a great partner who has the marketing savvy and financial backing to extract the most value out of CPI-300. That leads me to my second point regarding the significance of this deal to IntelGenx: In my opinion CPI-300 will provide IntelGenx the financial platform to aggressively accelerate and expand its pharmaceutical thin-film business. Thin-films are the big opportunity in IntelGenx' portfolio. Whether it is drugs for erectile dysfunction, insomnia or migraine, each of these products represent bigger opportunities for IntelGenx than CPI-300. With Reckitt Benckiser's suboxone film (one of only two FDA approved thin films) apparently trending toward $1B in annual sales, it is clear that the market and FDA are receptive to this new delivery system. Fortunately IntelGenx has a number of products through pilot human studies and one product (migraine) due to enter pivotal studies shortly, so they would appear to be well positioned with a number of nearer term thin-film projects. With all this in mind, I believe that Edgemont and CPI-300 provide a means to a much more lucrative end, that being IntelGenx becoming the world leader in the growing area of thin film drug delivery and development.


                                                                                                                                                                                  The following info is now based on IGXT's own SEC filings

Industry: Bio-technology

Market Capitalization: 30.46 Million 

Issued Shares: 63.1 Million

Fully Diluted Shares: 72 Million

Float Shares: 56.9 Million

Insider and Institutional Ownership: 18% 


Latest News

  •                                                                                                                                                                                                                                                                        (Click on Date for link to news article)

Intelgenx Announces Management Changes


Intelgenx Announces Equity Analyst Coverage by H.C. Wainwright


Intelgenx and RedHill Biopharma Report Positive Bioavailability Study Results in Support of Planned European Marketing Application in Q3/2014 for Anti-Migraine VersaFilm(TM) Product


Intelgenx Reports Q1 2014 results and provides corporate developement update


Intelgenx Announces government of canada funding for cNS VersaFilm(TM) project


Intelgenx and Redhill Biopharma Announce Commencement of a Bioavailability Study with Anti-Migraine VersaFilm(TM) Product to support european marketing application planned for q3/2014



and RedHill Biopharma Provide an Update on FDA's Ongoing Review of the NDA for Migraine VersaFilm(TM) Product


Intelgenx Announces Receipt of an Additional U.S. Patent Allowance Related To Proprietary Technology


Intelgenx and RedHill Biopharma Submit Response to FDA CRL for VersaFilm(TM) Product for Migraines


Intelgenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm


IntelGenx Announces Additional Developement and Commercialization with Par for Two More Products


IntelGenx Corp. Receives Buprenorphine/Naloxone Sublingual Film Product Patent Infringement Complaint


IntelGenx Receives Paragraph IV Certification Letter on Submission of ANDA for Forfivo XL™


IntelGenx Reports Q2, 2013 Results and Corporate Development Highlights


Time To Revalue IntelGenx- 2 More Products Being Reviewed By The FDA For Approval



Announces Submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction


Small-Cap Biotechs with Blockbuster Potential: Hugh Cleland


IntelGenx Announces FDA Acceptance of New Drug Application for Anti-Migraine VersaFilm(TM) Oral Film Product


IntelGenx Reports Q1, 2013 Results and Provides Operational Update


IntelGenx secures leadership Succession


IntelGenx submits New Drug Application for Anti-Migraine VersaFilm(TM)


IntelGenx Announces Commercial Launch of Forfivo XL(TM) in USA


  IntelGenx Reports Second Quarter 2012 Results and Highlights Recent Developments


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
IGXT News: Current Report Filing (8-k) 09/17/2014 10:01:01 AM
IGXT News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 09/04/2014 01:14:18 PM
IGXT News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 09/04/2014 01:12:20 PM
IGXT News: Current Report Filing (8-k) 08/21/2014 02:21:23 PM
IGXT News: Quarterly Report (10-q) 08/07/2014 08:00:59 AM
#10750  Sticky Note IntelGenx (TSX-V:IGX) (OTCQX:IGXT) to Present at the Stockmountie 08/21/14 02:23:42 PM
#10517  Sticky Note IntelGenx (TSX-V:IGX) (OTCQX:IGXT) and RedHill Biopharma Report Stockmountie 05/21/14 08:09:54 AM
#10764   Guess I'm not surprised .... chemist72 09/19/14 08:08:02 AM
#10763   New Hugh Cleland Life Sciences Report interview and GaryJPalys 09/19/14 05:12:25 AM
#10762   IntelGenx (TSXV: IGX) (OTCQX: IGXT) to Present at Stockmountie 09/17/14 09:49:33 AM
#10761   The stock price is perfectly aligned with the specular 09/10/14 09:51:30 AM
#10760   Will believe it when I see it. In kyouter 09/09/14 11:07:08 PM
#10759   Why don't you just try staying in touch specular 09/09/14 04:52:30 PM
#10758   Prove it! I don't see anything coming. kyouter 09/09/14 04:26:37 PM
#10757   They will not be announcing a new CEO specular 09/09/14 02:31:05 PM
#10756   None that I'm aware of. specular 09/02/14 04:24:41 PM
#10755   Did Khosla ever do a single presentation? GaryJPalys 09/02/14 04:10:28 PM
#10754   Gary I was told last week that they specular 09/02/14 09:52:36 AM
#10753   That's the best way to trade it Spec! GaryJPalys 08/29/14 04:21:37 PM
#10752   spec, thought you gave up on this dog - chemist72 08/29/14 02:31:16 PM
#10751   got back in today when it dipped back specular 08/29/14 02:07:37 PM
#10750   IntelGenx (TSX-V:IGX) (OTCQX:IGXT) to Present at the Stockmountie 08/21/14 02:23:42 PM
#10749   Hey thanks Gary for your quick DD got mentalist 08/19/14 03:35:24 AM
#10748   I do keep a eye on it, but GaryJPalys 08/18/14 04:59:47 PM
#10747   I hear you Gary, but they do have specular 08/18/14 04:56:53 PM
#10746   I don't know what it is, but I GaryJPalys 08/18/14 04:43:44 PM
#10745   The ONLY chance for moving the stock is specular 08/18/14 04:41:25 PM
#10744   Your guess is as good as mine... According GaryJPalys 08/18/14 04:17:16 PM
#10743   Hi Gary, mentalist 08/18/14 03:44:38 PM
#10742   I find it amazing how many people believe GaryJPalys 08/16/14 06:30:04 AM
#10741   Spec, it's from June... Seems Pacific Therapeutics is GaryJPalys 08/15/14 02:58:06 PM
#10740   I couldn't find it. Did Wainwright happen to specular 08/15/14 12:37:09 PM
#10739   H.C. Wainwright Initiates Coverage of Pacific Therapeutics Partner Stockmountie 08/15/14 09:32:51 AM
#10737   Rodman and Renshaw plbiinvestor 08/11/14 11:33:07 AM
#10736   Oversold, cheap & lots of buzz. nightowwl 08/10/14 05:02:32 PM
#10733   everyone should lighten up. this company will be Tasso9 08/07/14 05:33:56 PM
#10732   Definitely a "sad" story up to this point. chemist72 08/07/14 12:50:24 PM
#10731   The patent is a technology or compositional - specular 08/07/14 12:43:23 PM
#10730   Ho hum from market today on 10-Q - chemist72 08/07/14 10:54:02 AM
#10729   Agree spec, wonder what termination clause in their mopn up 08/07/14 10:51:07 AM
#10728   They have the ONLY single dose max offering specular 08/07/14 10:27:17 AM
#10727   Sales of Forfivo may increase based on IGXT killers_420 08/07/14 10:20:10 AM
#10726   Yeah well the big - negative - news specular 08/07/14 10:08:36 AM
#10725   Forfivo Royalty Revenue: killers_420 08/07/14 09:17:10 AM
#10724   IntelGenx (TSXV: IGX) (OTCQX: IGXT) Reports Q2, 2014 Stockmountie 08/07/14 08:06:26 AM
#10723   Sorry, was away for the weekend. Didn't see railroadman 08/04/14 01:51:03 PM
#10722   Hello Gary, railroadman 08/04/14 01:48:21 PM
#10721   The market may crash, but IGXT incompetence will chemist72 08/03/14 08:50:14 PM
#10720   Ok, I am going to go out on GaryJPalys 08/03/14 08:40:23 AM
#10719   Could you be a little more specific, like GaryJPalys 08/03/14 08:35:17 AM
#10718   OK, I give up - chemist72 08/01/14 12:38:05 PM
#10716   ED! Reviewing another holding found a item interesting railroadman 08/01/14 06:26:35 AM
#10715   Good question - chemist72 07/30/14 10:08:46 PM
#10714   Can they break the contract if the estimated railroadman 07/30/14 06:52:41 PM
#10713   To me, that IS the point - chemist72 07/30/14 03:38:55 PM
#10712   That's not the point - think harder. specular 07/30/14 03:26:52 PM
#10711   What do you expect from a "small-time" marketer? chemist72 07/30/14 03:21:00 PM